Celldex Therapeutics (NASDAQ:CLDX) Stock Rating Reaffirmed as Buy by HC Wainwright

Posted by on Oct 2nd, 2026

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $64.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 99.58% from the company’s previous close.

Several other equities research analysts have also commented on the stock. Barclays boosted their price target on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Friday, July 17th. Stifel Nicolaus set a $68.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, September 22nd. Cantor Fitzgerald boosted their target price on shares of Celldex Therapeutics from $61.00 to $72.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 22nd. Finally, Canaccord Genuity Group reduced their price target on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.92.

Get Our Latest Stock Analysis on Celldex Therapeutics

Celldex Therapeutics Price Performance

NASDAQ CLDX traded down $0.11 during trading hours on Friday, reaching $32.07. The company’s stock had a trading volume of 519,709 shares, compared to its average volume of 1,054,588. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -7.38 and a beta of 0.90. The company’s 50-day moving average is $38.45 and its two-hundred day moving average is $34.91. Celldex Therapeutics has a 1-year low of $22.10 and a 1-year high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.12. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.74 million. Equities analysts forecast that Celldex Therapeutics will post -4.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its stake in shares of Celldex Therapeutics by 11.5% in the second quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company’s stock worth $355,120,000 after buying an additional 983,195 shares in the last quarter. Commodore Capital LP grew its stake in Celldex Therapeutics by 5.1% during the 1st quarter. Commodore Capital LP now owns 2,696,616 shares of the biopharmaceutical company’s stock valued at $85,537,000 after acquiring an additional 131,616 shares in the last quarter. Eversept Partners LP raised its holdings in Celldex Therapeutics by 24.6% in the 1st quarter. Eversept Partners LP now owns 1,788,016 shares of the biopharmaceutical company’s stock valued at $56,716,000 after acquiring an additional 353,291 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Celldex Therapeutics by 62.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,059,534 shares of the biopharmaceutical company’s stock worth $33,596,000 after purchasing an additional 407,818 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Celldex Therapeutics by 438.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 788,696 shares of the biopharmaceutical company’s stock worth $29,347,000 after purchasing an additional 642,171 shares during the last quarter.

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.

Read More

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.